Author: Hongyi Chen; Zhicheng Zhang; Li Wang; Zhihua Huang; Fanghua Gong; Xiaodong Li; Yahong Chen; Jinzi J. WU
Title: First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients Document date: 2020_3_24
ID: b3y9zxjr_1
Snippet: absence of interferon nebulization (the background therapy). 10 patients were planned to be enrolled and actually 11 patients were enrolled. All patients were moderate COVID-19 patients per China National Standards [14] . These patients were recruited and screened, and eligible patients were enrolled and treated with danoprevir boosted by ritonavir in the presence or absence of interferon nebulization (as the background therapy) for 4 to12 days u.....
Document: absence of interferon nebulization (the background therapy). 10 patients were planned to be enrolled and actually 11 patients were enrolled. All patients were moderate COVID-19 patients per China National Standards [14] . These patients were recruited and screened, and eligible patients were enrolled and treated with danoprevir boosted by ritonavir in the presence or absence of interferon nebulization (as the background therapy) for 4 to12 days until being discharged from the hospital. Treatment naïve patients never received any antiviral therapies such as lopinavir/ritonavir and interferon nebulization prior to the treatment of danoprevir boosted by ritonavir. Treatment experienced patients had received at least one dose of any antiviral therapies such as lopinavir/ritonavir and interferon nebulization prior to the treatment of danoprevir boosted by ritonavir. Treatment regimen and dosing frequency are: (1) danoprevir, 100 mg per tablet, 1 tablet at a time, twice per day; (2) ritonavir, 100 mg per tablet, 1 tablet at a time, twice per day; (3) if administered, aerosol inhalation of αinterferon (interferon nebulization), 5 million units at a time, twice per day.
Search related documents:
Co phrase search for related documents- absence presence and background therapy: 1, 2
- absence presence and dose frequency: 1
- absence presence and hospital discharge: 1, 2, 3, 4
- aerosol inhalation and antiviral therapy: 1, 2, 3, 4
- aerosol inhalation and hospital discharge: 1, 2, 3
- antiviral therapy and background therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- antiviral therapy and dose frequency: 1
- antiviral therapy and hospital discharge: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral therapy and interferon nebulization: 1, 2, 3
- background therapy and eligible patient: 1
- background therapy and hospital discharge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- dose frequency and hospital discharge: 1
- eligible patient and hospital discharge: 1, 2
Co phrase search for related documents, hyperlinks ordered by date